HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER
Clinical safety rating: safe
Other drugs that affect hemostasis increase bleeding risk Can cause heparin-induced thrombocytopenia (HIT) and bleeding.
Heparin binds to antithrombin III, causing a conformational change that accelerates the inactivation of thrombin (factor IIa) and factor Xa. This inhibits fibrin formation and prevents clot propagation. Dextrose 5% provides a source of calories and fluid.
| Metabolism | Heparin is partially metabolized by the liver (via heparinase) and the reticular endothelial system to inactive metabolites (uroheparin). Desulfation and depolymerization occur. Renal excretion of metabolites. |
| Excretion | Renal: 40-50% as unchanged heparin (saturable); reticuloendothelial system: partial metabolism to uroheparin (less active); fecal: minimal (<5%). |
| Half-life | Terminal elimination half-life: 1-2 hours (dose-dependent, prolonged with higher doses due to saturable clearance). In hepatic or renal impairment: 1.5-3 hours. Clinical context: Twice-daily dosing may not maintain therapeutic levels; monitoring aPTT is essential. |
| Protein binding | 80-90% bound primarily to antithrombin III, with additional binding to albumin and other plasma proteins. |
| Volume of Distribution | 0.05-0.1 L/kg (confined to plasma volume; does not distribute into extravascular spaces). Clinical meaning: Indicates minimal tissue distribution; heparin acts in the intravascular compartment. |
| Bioavailability | Subcutaneous: 20-30% (due to limited absorption at injection site and binding to macrophages); Intravenous: 100%. |
| Onset of Action | Intravenous: immediate (within minutes); Subcutaneous: 20-30 minutes (delayed due to depot absorption). |
| Duration of Action | Intravenous: 2-6 hours (dose-dependent; continuous infusion required for sustained effect); Subcutaneous: 8-12 hours (low-dose prophylaxis). Note: Effects persist up to 2-4 hours after discontinuation of IV infusion. |
| Molecular Weight | 15000 |
For therapeutic anticoagulation in adults, heparin is administered intravenously as an initial bolus of 80 units/kg followed by a continuous infusion of 18 units/kg/hour, with dose adjustment based on activated partial thromboplastin time (aPTT) targeting 1.5-2.5 times control. The concentration of heparin sodium 25,000 units and dextrose 5% in plastic container is typically used for continuous infusion at a rate calculated to deliver the prescribed units per hour.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment for renal impairment is required as heparin is not significantly renally excreted. However, caution is advised in severe renal impairment (GFR <30 mL/min) due to potential for accumulation and increased bleeding risk; monitoring of aPTT is essential. |
| Liver impairment | In hepatic impairment, heparin clearance may be reduced due to decreased production of antithrombin III and altered coagulation factors. For Child-Pugh Class A: no adjustment, but monitor aPTT closely. For Child-Pugh Class B or C: consider dose reduction (e.g., 25-50% reduction in bolus and infusion rates) and frequent aPTT monitoring to avoid excessive anticoagulation. |
| Pediatric use | For pediatric patients, heparin is administered intravenously as an initial bolus of 75 units/kg (range 50-100 units/kg) followed by a continuous infusion: infants (age <1 year): 28 units/kg/hour; children (age >1 year): 20 units/kg/hour. Dose titrated to achieve aPTT of 60-85 seconds (or heparin level of 0.3-0.7 units/mL anti-Xa). Concentration of 25,000 units in 500 mL D5W (50 units/mL) is used; infusion rate (mL/hour) = (dose in units/kg/hour × weight in kg) / 50 units/mL. |
| 1st trimester | Heparin does not cross the placenta and is considered safe in pregnancy. No evidence of teratogenicity. |
| 2nd trimester | Safe for use. No increased risk of fetal harm. |
| 3rd trimester | Safe for use. Risk of maternal hemorrhage at delivery; monitor anticoagulation carefully. |
Clinical note
Other drugs that affect hemostasis increase bleeding risk Can cause heparin-induced thrombocytopenia (HIT) and bleeding.
| FDA category | Human |
| Placental transfer | Does not cross the placenta due to high molecular weight and negative charge. |
| Breastfeeding | Heparin is not excreted into breast milk due to its high molecular weight and polarity. Considered compatible with breastfeeding. |
■ FDA Black Box Warning
Heparin-induced thrombocytopenia (HIT) with thrombosis; monitor platelet counts closely. Spinal/epidural hematomas can occur with neuraxial anesthesia or spinal puncture, especially with concomitant use of other anticoagulants or antiplatelet drugs, leading to permanent paralysis.
| Common Effects | bleeding |
| Serious Effects |
Active major bleedingHistory of heparin-induced thrombocytopenia (HIT)Severe uncontrolled hypertensionRecent surgery with high bleeding riskHemophilia or other bleeding disorders
| Precautions | Heparin-induced thrombocytopenia (HIT) risk: monitor platelets every 2-3 days, Hemorrhage risk: caution with bleeding disorders, recent surgery, or concurrent anticoagulants, Hypersensitivity reactions (chills, fever, urticaria), Osteoporosis with prolonged use (>1 month), Hyperkalemia due to aldosterone suppression (especially in renal failure, diabetes), Priapism (rare) |
Loading safety data…
| Geriatric use | Elderly patients (age >65 years) are at increased risk of bleeding. Lower initial doses are recommended: consider reducing bolus to 50 units/kg and infusion to 15 units/kg/hour, with careful titration based on aPTT. Monitor renal function (creatinine clearance) as age-related decline may affect heparin clearance despite minimal renal excretion; also monitor for signs of bleeding more frequently. |
| Lactation Rating | L1 - Safe |
| Teratogenic Risk | Heparin does not cross the placenta, thus is not associated with teratogenicity. No fetal risk in first trimester. In second/third trimester, use is safe but risk of maternal hemorrhage and fetal bleeding if coagulation abnormalities occur. |
| Fetal Monitoring | Monitor maternal platelet count (risk of heparin-induced thrombocytopenia), coagulation parameters (aPTT, anti-Xa), signs of hemorrhage, and fetal surveillance (ultrasound growth, non-stress test) if used for extended periods in pregnancy. |
| Fertility Effects | No evidence of adverse effects on fertility. Heparin does not impair spermatogenesis or oogenesis. No impact on conception or implantation. |
| Food/Dietary |
| No specific food interactions with heparin. However, foods high in vitamin K (e.g., leafy greens, broccoli, Brussels sprouts) may theoretically affect coagulation if administered with warfarin, but heparin is not vitamin K-dependent. Ensure consistent dietary habits to avoid fluctuations in clotting parameters if transitioning to warfarin. |
| Clinical Pearls | This is a fixed combination of heparin (25,000 units) and dextrose 5% in a plastic container (typically 500 mL bag yielding 50 units/mL heparin). Heparin is an anticoagulant; dextrose provides calories and may affect insulin secretion. Do not use as a routine flush; it is intended for therapeutic anticoagulation (e.g., DVT, PE). Monitor aPTT closely (target 1.5-2.5 times control). Heparin can cause heparin-induced thrombocytopenia (HIT); check platelets at baseline and regularly. Use with caution in patients with renal impairment, bleeding disorders, or recent surgery. Plastic container may contain DEHP; avoid in neonates or pregnant women if alternatives exist. |
| Patient Advice | This medication contains heparin to prevent blood clots and sugar (dextrose) for calories. · You will have regular blood tests (aPTT) to check the blood's clotting time and adjust the dose. · Watch for signs of bleeding: unusual bruising, blood in urine or stool, coughing up blood, bleeding gums, or heavy menstrual flow. · Avoid aspirin, ibuprofen, naproxen, and other NSAIDs unless prescribed by your doctor, as they increase bleeding risk. · Report any symptoms of a serious reaction: difficulty breathing, rash, fever, or pain/swelling at the injection site. · Do not stop or change the infusion rate; it is given under strict medical supervision. |